Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cybin Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CYBN
American
8731
https://www.cybin.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cybin Inc
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
- Feb 1st, 2023 12:30 pm
Cybin to Host Virtual R&D Day on February 28, 2023
- Jan 26th, 2023 12:30 pm
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- Jan 24th, 2023 2:33 am
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
- Jan 18th, 2023 12:30 pm
Trippy Trading: Top Psychedelic Stocks For 2023
- Jan 17th, 2023 10:00 am
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
- Jan 12th, 2023 12:30 pm
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
- Jan 8th, 2023 10:00 pm
Cybin Highlights 2022 Accomplishments and Milestones
- Dec 20th, 2022 1:00 pm
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
- Dec 6th, 2022 9:01 pm
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
- Nov 15th, 2022 1:00 pm
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
- Nov 14th, 2022 10:01 pm
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
- Nov 10th, 2022 1:00 pm
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
- Nov 3rd, 2022 12:00 pm
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
- Nov 1st, 2022 12:00 pm
Cybin’s EMBARK Program Announces Graduation of Facilitators
- Oct 27th, 2022 12:00 pm
Cybin & The Chopra Foundation Recognize World Mental Health Day
- Oct 10th, 2022 4:00 pm
Cybin Provides Update on its Intellectual Property Portfolio
- Oct 6th, 2022 12:00 pm
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
- Sep 27th, 2022 12:00 pm
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
- Sep 27th, 2022 11:30 am
Cybin to Participate in Upcoming Scientific and Investor Conferences
- Sep 21st, 2022 12:00 pm
Scroll